Dr. Oleg Volkov has been appointed to the position of medical director of angioline company
ANGIOLINE company announces the appointment of Dr. Oleg Volkov as Medical Director. His area of responsibility will consist of the issues connected to clinical research study management, monitoring of clinical application of the products manufactured by the company, cooperation with professional opinion leaders, as well as identification of needs of medical practitioners for new innovation products and product development.
After graduation with honors from the Therapeutic Department of the Russian State Medical University in Moscow, Dr. Oleg Volkov underwent clinical studies in cardiology at the Russian Cardiologic Research and Production Complex of the Ministry of Health of the Russian Federation, and upon their completion, he worked as a cardiologist and X-ray surgeon in a number of leading Moscow clinics. In 2013, Dr. Oleg Volkov underwent refresher courses in X-Ray Endovascular Diagnostics and Treatment at the Russian Medical Academy of Advanced Studies and is a certified specialist in this area.
In addition to his medical activities, during the last 10 years, Dr. Oleg Volkov worked at the representative offices of Western manufacturers of the instruments and equipment for X-ray endovascular diagnostics and treatment such as Boston Scientific and Abbott Vascular.
“In the past few years, ANGIOLINE Company worked its way up from the small manufacturer to the key player in the Russian market of devices for X-ray endovascular diagnostics and treatment. I believe in great potential of Russian manufacturers and hope that employment with this dynamically developing company will allow me to participate in strategic decision making of various levels,” Dr. Oleg Volkov said. “In International Companies many decisions are made in the headquarters and usually there is no way to influence on them; therefore, foreign companies are unable to promptly adapt to changing needs of the Russian market”.
“Dr. Oleg Volkov is a recognized professional in his area,” noted Andrey Kudryashov, Director General of ANGIOLINE Company, “and we are sure that he will make his contribution to further development of our company in accordance with international standards.”